SS Innovations International (NASDAQ: SSII) Builds Telerobotic Surgery Position as Remote Procedures Gain Ground

Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, a recent article reads.
SS Innovations CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness.
The company reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations.
The company’s installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503.
SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.

The growing interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and its founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, in an increasingly relevant part of the surgical robotics market. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).

At a glance

Company: SS Innovations International
Ticker: NASDAQ: SSII
Announcement: Expansion

Key figures

Robotic telesurgeries as of Sept 28, 2026: 195
Installed SSi Mantra systems as of September 28: 244
Installed-base increase from the end of 2025: 45%
Cumulative procedures: 14,503
Countries reached: 12

People

Dr. Sudhir SrivastavaFounder and CEO; cardiac surgeon

Products and programs

SSi Mantra

For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the…

In brief

SS Innovations International says its SSi Mantra robotic system had been used in 195 remote surgeries by September 28, 2026, including heart operations and procedures conducted over long distances. The company also reported an installed base of 244 systems, 45% higher than at the end of 2025, and 14,503 procedures overall. The system is now present in 12 countries, with cardiac-surgery initiatives recently started in Colombia and Sri Lanka and a program added at HCG Hospital in Ahmedabad. CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery involves teleoperation, with responsiveness over distance a key technical issue. SS Innovations is seeking U.S. FDA clearance and European Union CE marking as it pursues wider international availability.

Key takeaways

SS Innovations reported 195 telesurgeries using its SSi Mantra system as of September 28, 2026.
The installed base was 244 systems, up 45% from the end of 2025.
The system has reached 12 countries, with recent cardiac programs in Colombia and Sri Lanka.
The company is pursuing U.S. FDA clearance and European Union CE marking.

SEC filings

Earlier from SS Innovations International

Back to News Center

SS Innovations International (NASDAQ: SSII) Builds Telerobotic Surgery Position as Remote Procedures Gain Ground